Kintor Pharmaceutical Completes KT‑939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential
CompanyDrug

Kintor Pharmaceutical Completes KT‑939 Tyrosinase Inhibitor Safety Trial, Highlights Cosmetic Potential

Grand Pharma Secures CE Mark for SIR‑Spheres Y‑90, Expanding Liver‑Cancer Treatment Portfolio
CompanyDrug

Grand Pharma Secures CE Mark for SIR‑Spheres Y‑90, Expanding Liver‑Cancer Treatment Portfolio

Chongqing Genrix Bio Secures NMPA Approval for GR2303, a Novel TL1A‑Targeting Antibody in IBD
CompanyDrug

Chongqing Genrix Bio Secures NMPA Approval for GR2303, a Novel TL1A‑Targeting Antibody in IBD

Fosun Pharma Secures Foritinib Approval for ALK‑NSCLC Trials, Paving Way for Targeted Therapy
CompanyDrug

Fosun Pharma Secures Foritinib Approval for ALK‑NSCLC Trials, Paving Way for Targeted Therapy

Duality Biotherapeutics Hits PFS Milestone with DB‑1303/BNT323 in HER2‑Positive Breast Cancer
CompanyDrug

Duality Biotherapeutics Hits PFS Milestone with DB‑1303/BNT323 in HER2‑Positive Breast Cancer

Innovent Biologics Announces Strong Phase II Results for Tigulixostat in Chinese Gout Patients
CompanyDrug

Innovent Biologics Announces Strong Phase II Results for Tigulixostat in Chinese Gout Patients

XWPharma Secures $205 M Valiloxybate Deal with Avadel
CompanyDeals

XWPharma Secures $205 M Valiloxybate Deal with Avadel

FDA Launches “Green List” to Shield U.S. Markets from Unsafe GLP‑1 APIs
Policy / Regulatory

FDA Launches “Green List” to Shield U.S. Markets from Unsafe GLP‑1 APIs

InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL
CompanyDrug

InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL

Regenelead Secures NMPA Approval for RGL‑305 Cell Therapy in Advanced Malignant Tumors
CompanyDrug

Regenelead Secures NMPA Approval for RGL‑305 Cell Therapy in Advanced Malignant Tumors

Takeda Secures FDA Approval for VONVENDI’s Expanded Use in Adult and Pediatric VWD
CompanyDrug

Takeda Secures FDA Approval for VONVENDI’s Expanded Use in Adult and Pediatric VWD

QuantumPharm XtalPi Secures Phase I Approval for PEP08, a Next‑Generation PRMT5 Inhibitor
CompanyDrug

QuantumPharm XtalPi Secures Phase I Approval for PEP08, a Next‑Generation PRMT5 Inhibitor